Merus Labs International (TSE:MSL) Raised to “Strong-Buy” at Leerink Partners

Merus Labs International (TSE:MSL) (NASDAQ:MSLI) was upgraded by analysts at Leerink Partners to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Separately, Cantor Fitzgerald raised Merus Labs International to a “strong-buy” rating in a research note on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Strong Buy”.

Merus Labs International Stock Performance

Merus Labs International has a one year low of C$0.95 and a one year high of C$1.76.

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.